Efanesoctocog alfa at a glance
Medicine class
Recombinant factor VIII replacement therapy
Licensed use
Prevention and treatment of bleeding in moderate or severe haemophilia A from age 2 years
Administration
Injection into a vein after mixing the supplied powder and solvent
Home treatment
A patient or caregiver may administer it after suitable training and clinical approval
What is Efanesoctocog alfa used for?
Licensed uses in people aged 2 years and over with moderate or severe haemophilia A include:
Preventing bleeding episodes.
Treating bleeding episodes.
Managing bleeding around surgery under specialist supervision.
How does Efanesoctocog alfa work?
It temporarily replaces missing factor VIII, supporting thrombin and fibrin formation so a stable blood clot can form. Its Fc, von Willebrand factor D'D3 and XTEN components prolong factor VIII activity in the circulation.
Efanesoctocog alfa preparations and strengths
Injection
Route: Parenteral
Strengths: 250 units, 500 units, 750 units, 1000 units, 2000 units, 3000 units, 4000 units
How to take Efanesoctocog alfa
Use only as instructed by the specialist haemophilia team. Mix the powder with the supplied solvent and inject it into a vein. Self-administration requires training.
Use aseptic technique and the supplied equipment.
Gently swirl the vial; do not shake it.
Use only a clear, colourless to slightly opalescent solution without particles.
Record the product name and batch number after each administration.
Do not mix it with other injection or infusion solutions.
Efanesoctocog alfa side effects
Common or expected effects
- Headache
- Joint pain
- Pain in an arm or leg
- Back pain
- Vomiting
- Fever
- Eczema, rash or hives
Get urgent medical advice
- Severe allergic reaction, including swelling, breathing difficulty, low blood pressure or collapse
- Factor VIII inhibitors, which may cause persistent bleeding or reduced treatment effect
Efanesoctocog alfa in pregnancy
Experience during pregnancy is very limited, and reproductive studies have not been conducted. Use should be considered only when clearly indicated, with advice from the haemophilia and maternity teams.
Efanesoctocog alfa while breastfeeding
Clinical experience during breastfeeding is lacking, so it is not known whether efanesoctocog alfa is suitable. Specialist advice is needed, and use should be limited to situations where it is clearly indicated.
Efanesoctocog alfa interactions
No medicine interactions have been reported for recombinant factor VIII products, but formal interaction studies with efanesoctocog alfa have not been performed. Tell the haemophilia team about all prescribed, over-the-counter and complementary products used.
Common questions about Efanesoctocog alfa
Answers are fully visible for fast scanning and source review.
Is efanesoctocog alfa used for haemophilia B?
No. It replaces factor VIII and is licensed for moderate or severe haemophilia A, not haemophilia B.
Can children use efanesoctocog alfa?
It is licensed from age 2 years for moderate or severe haemophilia A, but not below age 2.
Can it be injected at home?
Yes, if the haemophilia clinician considers this appropriate and the patient or caregiver has received practical training.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.